The Prison Economy of Needles and Syringes: What Opportunities Exist for Blood Borne Virus Risk Reduction When Prices Are so High?

by Carla Treloar, Luke McCredie, Andrew R Lloyd
Published 2016-01-01

Severe Eosinophilic Meningoencephalitis Secondary to Suspected Neuroangiostrongyliasis with a Good Clinical Outcome

by Fabian Chiong, Andrew R. Lloyd, Jeffrey J. Post
Published 2019-01-01

Violence and hepatitis C transmission in prison-A modified social ecological model.

by Hossain M S Sazzad, Luke McCredie, Carla Treloar, Andrew R Lloyd, Lise Lafferty
Published 2020-01-01

Hepatitis C Virus Epitope Immunodominance and B Cell Repertoire Diversity

by Nicholas A. Brasher, Anurag Adhikari, Andrew R. Lloyd, Nicodemus Tedla, Rowena A. Bull
Published 2021-05-01

Capacity of non-invasive hepatic fibrosis algorithms to replace transient elastography to exclude cirrhosis in people with hepatitis C virus infection: A multi-centre observational...

by Melissa Louise Kelly, Stephen M Riordan, Rohan Bopage, Andrew R Lloyd, Jeffrey John Post
Published 2018-01-01

Gene expression in response to exercise in patients with chronic fatigue syndrome: a pilot study.

by Andrew Keech, Ute Vollmer-Conna, Benjamin Kenneth Barry, Benjamin Kenneth Barry, Andrew R Lloyd
Published 2016-09-01

Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance

by Auda A. Eltahla, Fabio Luciani, Peter A. White, Andrew R. Lloyd, Rowena A. Bull
Published 2015-09-01

Envelope-Specific IgG3 and IgG1 Responses Are Associated with Clearance of Acute Hepatitis C Virus Infection

by Melanie R. Walker, Auda A. Eltahla, Michael M. Mina, Hui Li, Andrew R. Lloyd, Rowena A. Bull
Published 2020-01-01

Transmission of Hepatitis C Virus among Prisoners, Australia, 2005–2012

by Neil Arvin Bretaña, Lies Boelen, Rowena Bull, Suzy Teutsch, Peter A. White, Andrew R. Lloyd, Fabio Luciani
Published 2015-05-01

Adaptation of Oxford Nanopore technology for hepatitis C whole genome sequencing and identification of within-host viral variants

by Nasir Riaz, Preston Leung, Kirston Barton, Martin A. Smith, Shaun Carswell, Rowena Bull, Andrew R. Lloyd, Chaturaka Rodrigo
Published 2021-03-01

Personalised relaxation practice to improve sleep and functioning in patients with chronic fatigue syndrome and depression: study protocol for a randomised controlled trial

by Claire L. Macnamara, Erin Cvejic, Gordon B. Parker, Andrew R. Lloyd, Gina Lee, Jessica E. Beilharz, Ute Vollmer-Conna
Published 2018-07-01

Per-event probability of hepatitis C infection during sharing of injecting equipment.

by Lies Boelen, Suzy Teutsch, David P Wilson, Kate Dolan, Greg J Dore, Andrew R Lloyd, Fabio Luciani, HITS investigators
Published 2014-01-01

Understanding the Determinants of BnAb Induction in Acute HCV Infection

by Alexander P. Underwood, Melanie R. Walker, Nicholas A. Brasher, Auda A. Eltahla, Lisa Maher, Fabio Luciani, Andrew R. Lloyd, Rowena A. Bull
Published 2018-11-01

Toward DNA-Based T-Cell Mediated Vaccines to Target HIV-1 and Hepatitis C Virus: Approaches to Elicit Localized Immunity for Protection

by Zelalem A. Mekonnen, Branka Grubor-Bauk, Makutiro G. Masavuli, Ashish C. Shrestha, Charani Ranasinghe, Rowena A. Bull, Andrew R. Lloyd, Eric J. Gowans, Danushka K. Wijesundara
Published 2019-04-01

Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection.

by Rowena A Bull, Fabio Luciani, Kerensa McElroy, Silvana Gaudieri, Son T Pham, Abha Chopra, Barbara Cameron, Lisa Maher, Gregory J Dore, Peter A White, Andrew R Lloyd
Published 2011-09-01

Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infection.

by Jordan J Feld, Jason Grebely, Gail V Matthews, Tanya Applegate, Margaret Hellard, Alana Sherker, Vera Cherepanov, Kathy Petoumenos, Barbara Yeung, John M Kaldor, Andrew R Lloyd, Gregory J Dore
Published 2013-01-01

Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance

by Mark W. Douglas, Enoch S.E. Tay, Dao Sen Wang, Adrian T.L. Ong, Caroline Wilson, Amy Phu, Jen Kok, Dominic E. Dwyer, Rowena A. Bull, Andrew R. Lloyd, Tanya L. Applegate, Gregory J. Dore, Anita Y. Howe, Richard Harrigan, Jacob George
Published 2020-06-01

Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design.

by Zhen-Yong Keck, Brian G Pierce, Patrick Lau, Janine Lu, Yong Wang, Alexander Underwood, Rowena A Bull, Jannick Prentoe, Rodrigo Velázquez-Moctezuma, Melanie R Walker, Fabio Luciani, Johnathan D Guest, Catherine Fauvelle, Thomas F Baumert, Jens Bukh, Andrew R Lloyd, Steven K H Foung
Published 2019-05-01

Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study.

by Behzad Hajarizadeh, Bart Grady, Kimberly Page, Arthur Y Kim, Barbara H McGovern, Andrea L Cox, Thomas M Rice, Rachel Sacks-Davis, Julie Bruneau, Meghan Morris, Janaki Amin, Janke Schinkel, Tanya Applegate, Lisa Maher, Margaret Hellard, Andrew R Lloyd, Maria Prins, Gregory J Dore, Jason Grebely, InC3 Study Group
Published 2015-01-01

Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection

by Arunasingam Abayasingam, Harikrishnan Balachandran, David Agapiou, Mohamed Hammoud, Chaturaka Rodrigo, Elizabeth Keoshkerian, Hui Li, Nicholas A. Brasher, Daniel Christ, Romain Rouet, Deborah Burnet, Branka Grubor-Bauk, William Rawlinson, Stuart Turville, Anupriya Aggarwal, Alberto Ospina Stella, Christina Fichter, Fabienne Brilot, Michael Mina, Jeffrey J. Post, Bernard Hudson, Nicky Gilroy, Dominic Dwyer, Sarah C. Sasson, Fiona Tea, Deepti Pilli, Anthony Kelleher, Nicodemus Tedla, Andrew R. Lloyd, Marianne Martinello, Rowena A. Bull
Published 2021-04-01